Repeated courses of rituximab in chronic ITP: Three different regimens.
Repeated courses of rituximab in chronic ITP: Three different regimens.
复制标题
DOI：
10.1002/ajh.21512
复制
发表时间：
2009-10
影响因子：
12.8
通讯作者：
Bussel, James
中科院分区：
文献类型：
--
作者：
Hasan, Aisha;Michel, Marc;Patel, Vivek;Stasi, Roberto;Cunningham-Rundles, Susanna;Leonard, John P.;Bussel, James
This study investigated responses to re-treatment with rituximab in chronic ITP patients. Treatment with rituximab in chronic ITP patients induces long-lasting responses in approximately 30% of patients but even these patients may relapse. Twenty patients who had achieved a response to rituximab and relapsed were re-treated with rituximab (375 mg/m2 × 4); this data was analyzed retrospectively. Subsequently, 16 patients were prospectively randomized to receive rituximab with CVP (R-CVP) or double dose rituximab (DDR). Re- treatment with standard dose rituximab demonstrated responses similar to initial rituximab treatment in 15 of 20 patients. Neither of the 2 more intensive regimens (R-CVP, DDR) induced responses in any patient who had previously failed to respond to rituximab nor induced substantially longer-lasting responses among previous responders. No additional toxicity was noted with the DDR regimen, whereas R-CVP was not well tolerated. These results suggest that re-treatment with standard dose rituximab induces similar responses in 75% of previously responding patients and is well tolerated. Neither combining rituximab with CVP nor doubling the dose of rituximab increased the response rate.
登录
查看更多内容
影响因子：
--
作者：
Cohen, YC;Djulbegovic, B;Mozes, B
通讯作者：
Mozes, B
影响因子：
12.8
作者：
Kuwana, M.;Iki, S.;Urabe, A.
通讯作者：
Urabe, A.
影响因子：
45.3
作者：
O'Brien, SM;Kantarjian, H;Keating, MJ
通讯作者：
Keating, MJ
影响因子：
20.3
作者：
Marcus, R;Imrie, K;Smith, P
通讯作者：
Smith, P
影响因子：
20.3
作者：
Carson, Kenneth R.;Evens, Andrew M.;Bennett, Charles L.
通讯作者：
Bennett, Charles L.